Table 4. Risk factors for SARS-CoV-2 antibody positivity.
| Parameter | SARS-CoV-2 antibody positive (n=36) | SARS-CoV-2 antibody negative (n=105) | p-value | |
|---|---|---|---|---|
| Age (yr) | 11.6±4.5 | 11.1±4.5 | 0.97 | |
| Sex, female | 21 (58.3) | 60 (57.1) | 0.9 | |
| Duration of disease (yr) | 4.6±3.0 | 4.6±3.2 | 0.89 | |
| COVID-19 related symptoms | 17 (47.2) | 15 (14.2) | 0.00004 | |
| Close contact with a SARS-CoV-2 PCR-positive patient | 25 (69.4) | 20 (19.0) | <0.00001 | |
| HL+ subjects | 26 (72.2) | 27 (25.7) | <0.00001 | |
| Immunosuppressive usage | 14 (38.8) | 35 (33.3) | 0.54 | |
| Number of immunosuppressives | ||||
| Polydrug | 4 (11.1) | 13 (12.3) | 0.83 | |
| Type of immunosuppression | 0.27 | |||
| Antimetabolites | 6 (16.6) | 24 (22.8) | ||
| Selective cytokine inhibitors | 4 (11.1) | 10 (9.5) | ||
| Biological agents | 2 (5.5) | 3 (2.8) | ||
| Corticosteroids | 3 (8.3) | 2 (1.9) | ||
| Primary diagnosis | 0.68 | |||
| Hepatic disorders | 10 (27.7) | 39 (37.1) | ||
| Gastrointestinal tractus diseases | 18 (50.0) | 50 (47.6) | ||
| Cystic fibrosis | 3 (8.3) | 6 (5.7) | ||
| Post-liver transplantation | 5 (13.8) | 10 (9.5) | ||
| Primary disease activation/flare | 3 (8.3) | 15 (14.2) | 0.35 | |
Values are presented as mean±standard deviation or number (%).
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, HL: high likelihood.